109 related articles for article (PubMed ID: 35587018)
1. Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France.
Grumberg V; Chouaïd C; Cotté FE; Jouaneton B; Jolivel R; Gaudin AF; Reynaud D; Assié JB; Borget I
J Med Econ; 2022; 25(1):691-699. PubMed ID: 35587018
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden of Checkpoint Inhibitor Immunotherapy for the Treatment of Non-Small Cell Lung Cancer in US Clinical Practice.
Nesline MK; Knight T; Colman S; Patel K
Clin Ther; 2020 Sep; 42(9):1682-1698.e7. PubMed ID: 32747004
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of patients with advanced non-small-cell lung cancer receiving nivolumab versus chemotherapy in China.
Chai Q; Shen Y; Du J; Zhu J; Wu B
Immunotherapy; 2020 Mar; 12(4):245-254. PubMed ID: 32189542
[No Abstract] [Full Text] [Related]
4. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
5. Health Care Resource Utilization and Economic Burden Associated With Congenital Cytomegalovirus Infection: A Longitudinal Analysis of Data From Clinical Practice at a Large Health Care Provider in Israel.
Weil C; Wang WV; Marks MA; Bilavsky E; Sinha A; Chodick G; Goodman E
Clin Ther; 2022 Feb; 44(2):282-294. PubMed ID: 35115189
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
Marine S; Stéphane R; Nicolas P; Felizzi F; Paracha N; Benjamin M; Perol M
J Med Econ; 2020 May; 23(5):464-473. PubMed ID: 31951770
[No Abstract] [Full Text] [Related]
7. Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab.
Chouaïd C; Grumberg V; Batisse A; Corre R; Giaj Levra M; Gaudin AF; Prodel M; Lortet-Tieulent J; Assié JB; Cotté FE
JCO Clin Cancer Inform; 2022 Feb; 6():e2100108. PubMed ID: 35113656
[TBL] [Abstract][Full Text] [Related]
8. Characteristics, management, and healthcare resources of patients with advanced non-small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis.
Assié JB; Grumberg V; Reynaud D; Gaudin AF; Batisse A; Jolivel R; Jouaneton B; Cotté FE; Chouaïd C
Respir Med Res; 2023 Nov; 84():101051. PubMed ID: 37897879
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
10. Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe.
Verleger K; Penrod JR; Manley Daumont M; Solem C; Luo L; Macahilig C; Hertel N
Clinicoecon Outcomes Res; 2020; 12():23-33. PubMed ID: 32021337
[TBL] [Abstract][Full Text] [Related]
11. Costs of non-small cell lung cancer in the Netherlands.
van der Linden N; Bongers ML; Coupé VM; Smit EF; Groen HJ; Welling A; Schramel FM; Uyl-de Groot CA
Lung Cancer; 2016 Jan; 91():79-88. PubMed ID: 26589654
[TBL] [Abstract][Full Text] [Related]
12. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.
Lee DH; Isobe H; Wirtz H; Aleixo SB; Parente P; de Marinis F; Huang M; Arunachalam A; Kothari S; Cao X; Donnini N; Woodgate AM; de Castro J
BMC Health Serv Res; 2018 Mar; 18(1):147. PubMed ID: 29490654
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC.
Li J; Zhang T; Xu Y; Lu P; Zhu J; Liang W; Jiang J
Immunotherapy; 2020 Oct; 12(14):1067-1075. PubMed ID: 32811247
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan.
Leung JH; Chang CW; Chan AL; Lang HC
Future Oncol; 2022 Mar; 18(7):859-870. PubMed ID: 35105168
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
16. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
[TBL] [Abstract][Full Text] [Related]
18. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of nivolumab in patients with NSCLC in the United States.
Chaudhary MA; Lubinga SJ; Smare C; Hertel N; Penrod JR
Am J Manag Care; 2021 Aug; 27(8):e254-e260. PubMed ID: 34460179
[TBL] [Abstract][Full Text] [Related]
20. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers.
Joseph RW; Shillington AC; Lee TA; Macahilig CP; Diede SJ; Dave V; Harshaw Q; Scherrer E; Liu FX
J Med Econ; 2020 Feb; 23(2):132-138. PubMed ID: 31750751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
